HDAC9 and melanoma: The combination of the HDAC inhibitor AR42 with the multi-kinase inhibitor pazopanib efficiently killed dabrafenib/trametinib-resistant melanoma cells by AIF-mediated necroptosis and toxic autolysosome formation.